Tata India Pharma & Healthcare Fund(IDCW)
Ticker: mf15828
Decent
68/100
☆ Add to Watchlist
More Options
U
UTI Banking and Financial Services Fund(IDCW)
The UTI Banking and Financial Services Fund shows decent potential but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
View details
M
Mirae Asset Overnight Fund(M-IDCW)
The fund shows decent potential but is facing challenges in profitability and growth drivers.
View details
M
Mirae Asset Overnight Fund(W-IDCW)
The fund shows a decent performance with stable growth and a solid balance sheet, making it a reasonable investment option.
View details
M
Mirae Asset Overnight Fund(DD-IDCW)
The fund shows decent potential but lacks strong growth drivers and competitive advantages.
View details
A
Aditya Birla SL Income Plus Arbitrage Active FOF(IDCW)
The fund shows decent potential with moderate risks, but investors should be cautious about execution and liquidity issues.
View details
A
Aditya Birla SL Income Plus Arbitrage Active FOF(IDCW Payout)
The fund shows decent potential with stable growth prospects, but investors should be cautious of execution risks and liquidity issues.
View details
D
DSP Natural Res & New Energy Fund(IDCW)
The fund is positioned in a promising sector with decent growth potential, but execution risks and mixed market sentiment warrant caution.
View details
D
DSP Natural Res & New Energy Fund(IDCW-Reinv)
The fund shows potential in a growing sector, but investors should be cautious of execution risks and liquidity issues.
View details
F
Franklin India Dynamic Asset Allocation Active FOFs(IDCW Payout)
The fund presents a decent investment opportunity with moderate growth potential and manageable risks.
View details
F
Franklin India Dynamic Asset Allocation Active FOFs(IDCW)
The fund shows decent potential with moderate risks; however, investors should be cautious about execution and liquidity issues.
View details
E
Edelweiss Large Cap Fund(IDCW)
The Edelweiss Large Cap Fund shows potential but has several areas of concern that could impact future performance.
View details
H
HDFC Housing Opp Fund(IDCW)
The HDFC Housing Opp Fund shows potential for growth with a decent risk profile, but investors should be cautious of execution risks.
View details
H
HDFC Housing Opp Fund(IDCW Reinvest)
The fund shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
B
Bajaj Finserv Balanced Advantage Fund(IDCW)
The fund shows decent potential with a balanced approach, but investors should be cautious of market conditions and execution risks.
View details
B
Bajaj Finserv Small Cap Fund(IDCW)
Bajaj Finserv Small Cap Fund shows potential for growth but comes with notable risks and valuation concerns.
View details
A
Axis Gold Fund(IDCW)
The Axis Gold Fund shows decent potential but faces challenges in profitability and liquidity. Investors should be cautious.
View details
Business Overview
Tata India Pharma & Healthcare Fund (IDCW) is a dedicated mutual fund that focuses on investing in the rapidly growing pharmaceutical and healthcare sectors in India. Ideal for investors seeking long-term growth and exposure to a robust industry, this fund aims to capitalize on the increasing demand for healthcare solutions. With a team of experienced fund managers, it offers a strategic approach to navigating market opportunities.
- Focuses on pharmaceutical and healthcare sectors
- Ideal for long-term growth investors
- Capitalizes on India's growing healthcare demand
- Managed by experienced professionals
- Diversified investment strategy for risk management
Investment Thesis
Tata India Pharma & Healthcare Fund presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital healthcare services, and attractive valuations compared to its peers. This fund is well-positioned to capitalize on the booming healthcare sector in India.
- Backed by the reputable Tata Group, ensuring strong governance and trust.
- Digital healthcare services are rapidly expanding, providing a robust growth runway.
- Valuations remain attractive compared to industry peers, offering potential upside.
- Focus on innovative healthcare solutions aligns with market trends.
- Diversified portfolio reduces risk while targeting high-growth segments.
Opportunity vs Risk
Opportunities
- Growing healthcare demand in India
- Government support for pharma sector
- Potential for high returns
- Diversification in healthcare investments
- Innovations in drug development
Risks ⚠️
- Regulatory changes impacting operations
- Market competition from global players
- Rising raw material costs
- Economic downturn affecting spending
- Dependence on few major clients
Peer Perspective
Tata India Pharma & Healthcare Fund trades at a slight premium compared to peers like SBI Healthcare Opportunities Fund and ICICI Prudential Pharma Fund. A rerating could occur with sustained growth acceleration and improved margin stability.
📊 Stock Investment Checklist (100 Points)
Tata India Pharma & Healthcare Fund(IDCW) • Updated: 2025-10-01 21:57:41
-
10BusinessHighPharmaceuticals are essential and have a strong growth outlook.
-
10GrowthHighConsistent revenue growth observed over the past few years.
-
10ProfitabilityHighROE and ROCE are above industry average, indicating good profitability.
-
8ValuationHighValuation metrics are reasonable compared to peers.
-
7BalanceHighDebt levels are manageable with adequate liquidity.
-
6GovernanceGoodPromoter holding is strong, but some concerns about disclosures.
-
5DriversGoodGrowth drivers are present, but execution risks exist.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
The fund shows decent potential with consistent growth and profitability, but some risks in governance and execution need to be monitored.